23.4.2026 15:44:26 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

The annual general meeting in Thor Medical ASA (the "Company") was held today, 23 April 2026.

All items on the agenda were approved in accordance with the notice. The minutes will be made available on https://www.thormedical.com/.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium, a key component of next-generation targeted cancer treatment. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides a reliable, environmentally friendly and cost-efficient supply of alpha emitters to the radiopharmaceutical industry. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by fueling next-generation cancer therapies with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.

Contacts

• Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reierth@thormedical.com

Attachments

• Download announcement as PDF.pdf